Our previous research suggested that bufadienolides could inhibit GBM via promoting ATP1A1 degradation.28 Thus, we examined whether ATP1A1 impacts the synergistic effect of TMZ and CS‐6. Here, ATP1A1 is linked to glioblastoma.